A novel anti-Alzheimer's disease drug, ladostigil neuroprotective, multimodal brain-selective monoamine oxidase and cholinesterase inhibitor.

Abstract

The novel therapeutic strategy in which drug candidates are designed to possess diverse pharmacological properties and act on multiple targets has stimulated the development of the multimodal drug, ladostigil [(N-propargyl-(3R) aminoindan-5yl)-ethyl methyl carbamate]. Ladostigil combines neuroprotective effects with monoamine oxidase-A and -B and cholinesterase inhibitory activities in a single molecule, presently in a Phase IIb clinical trial and intended for the treatment of Alzheimer's disease, and dementia comorbid with extrapyramidal disorders and depression. This chapter will discuss the preclinical scientific evidence for the therapeutic potential use of ladostigil in the clinic and molecular signaling pathways that are considered to be involved in the molecular activities of the drug.

• Authors: Orly Weinreb, Tamar Amit, Orit Bar-Am, Moussa B H Youdim
• Journal: International review of neurobiology (Int Rev Neurobiol) Vol. 100 Pg. 191-215 ( 2011) ISSN: 2162-5514 [Electronic] United States
• PMID: 21971009 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)
• Copyright: Copyright © 2011 Elsevier Inc. All rights reserved.

Chemical References

• (N-propargyl-(3R) aminoindan-5-yl)-ethyl methyl carbamate
• Cholinesterase Inhibitors
• Indans
• Monoamine Oxidase Inhibitors
• Neuroprotective Agents

Topics

• Alzheimer Disease (drug therapy, enzymology, pathology)
• Animals
• Brain (drug effects, enzymology, pathology)
• Cholinesterase Inhibitors (chemistry, pharmacology)
• Humans
• Indans (chemistry, pharmacology)
• Monoamine Oxidase Inhibitors (chemistry, pharmacology)
• Neuroprotective Agents (chemistry, pharmacology)